Published on
The Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program is a Children’s Hospital of Philadelphia (CHOP) Frontier Program within the Division of Hematology that aims to provide advanced clinical care of inherited bleeding disorders and develop breakthrough treatments through research.
Published on
CHOP experts in bleeding disorders care and research presented at the American Society of Hematology 2022 conference.
Published on
Nearly 50 faculty, staff and trainees from the Division of Hematology and Division of Oncology at Children’s Hospital of Philadelphia attended the 64th Annual American Hematology Society (ASH) Meeting in New Orleans, Louisiana.
Published on
In a short documentary by the New England Journal of Medicine, Dr. Alexis Thompson discusses the early successes of gene therapy, as well as its risks and benefits.
Published on
A leading study site for nearly a decade, CHOP will be part of a network of treatment centers in the country offering the therapy to patients who require regular blood transfusions.
Published on
CHOP researchers have discovered a new part of the regulatory cascade responsible for silencing fetal hemoglobin in adult cells.
Published on
A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.
Published on
CHOP researchers have identified two transcription factors that are involved in silencing fetal hemoglobin in adult red blood cells.
Published on
Prestigious award recognizes Dr. High’s contribution to improving children’s health through her gene therapy research, which began during her time at CHOP.
Published on
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).